The off-label use of prescriptions has come under scrutiny in the past few years and has led to several new developments in 2017 attempting to address the issue. Among such new changes are the Food and Drug Administration’s (FDA’s) modification of what constitutes “intended use” and Arizona’s law allowing manufacturers to communicate off-label uses of their products.
Access Exclusive Benefits
Members unlock unlimited content, networking opportunities, publications and more.
Health Law Section
- ABA Health eSource